During FY11, the Clinical Pharmacology Program (CPP) provided support to over 70 clinical trials. This support ranged from sample pickup and processing, to full analytical method development and validation, pharmacokinetic and pharmacogenetic analysis and assistance with trial design. In FY11, the CPP received over 9,000 biological samples including blood, urine and bone marrow aspirate. Upon arrival, all samples are processed, barcoded and frozen for future use. The first priority in characterizing the pharmacokinetics of an anticancer agent is to develop a reliable and reproducible analytical method for quantitating agents in biological fluids and tissues. The CPP utilizes high performance liquid chromatography (HPLC) coupled with state-of-the-art detection instruments including mass spectrometers, tandem mass spectrometers (MS/MS) and diode array detectors (for UV absorption) to measure drug concentrations. Following method development, assays are validated according to the FDA Guidelines for Bioanalytical Method Development. The CPP is currently focused on the method development, validation and subsequent human sample analyses for imatinib, belinostat, clopidogrel, bortezomib, and irinotecan. The CPP has previously developed analytical methods for a wide range of other therapeutics, including depsipeptide, TNP-470, phenylacetate, phenylbutyrate, tamoxifen, UCN-01, CAI, thalidomide, COL-3, suramin, melphalan, erlotinib, perifosine, SU5416, 2ME, MS-275, ketoconazole, lenalidomide, romidepsin, AZD2281 and gemicitabine, sorafenib, finasteride, nelfinavir, and 17-DMAG. Irinotecan drug eluting beads study: This is a Phase 1b study on transarterial chemoembolization (TACE) for the treatment of hepatic metastases using irinotecan drug-eluting beads. An analytical assay is developed and validated under development and validation for quantitation of irinotecan, SN-38 and SN-38G in porcine and human plasma, using LC-MS-MS technology. An analytical method for tissue samples is still under development for analysis of liver porcine samples to elucidate the tissue and systemic pharmacokinetics of irinotecan. To evaluate the pharmacokinetics (PK) of AZD2281 and gemcitabine as well as to assess for any potential drug-drug interaction, a sensitive and simple LC-MS method was recently developed to simultaneously determine drug concentrations of both AZD2281 and gemcitabine on patient samples derived from this trial. We have recently validated and published a simple, rapid and sensitive liquid chromatography/tandem mass spectrometric (LC/MS/MS) analytical method for quantification of Hsp90 inhibitor PF-04928473 in human plasma, following administration of its prodrug, PF-04929113 (SNX5422). We have developed a sensitive and rapid Ultra-HPLC-MS/MS method for the simultaneous detection of clopidogrel and its MPB-derivatized active thiol-metabolite in human plasma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICSC006536-18
Application #
8350174
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2011
Total Cost
$446,379
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Manasanch, Elisabet E; de Larrea, Carlos Fernández; Zingone, Adriana et al. (2017) Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leuk Lymphoma 58:639-645
Dao, Kim; Chtioui, Haithem; Lu, Yimin et al. (2017) Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. Am J Kidney Dis 69:553-554
Ferraz Nogueira Filho, Marco A; Peer, Cody J; Nguyen, Jeffers et al. (2017) A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. J Pharm Biomed Anal 132:223-226
Dao, Kim; Lu, Yimin; Peer, Cody J et al. (2017) Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemother Pharmacol 79:215-218
Lee, Jung-Min; Cimino-Mathews, Ashley; Peer, Cody J et al. (2017) Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escala J Clin Oncol 35:2193-2202
Uldrick, Thomas S; Gonçalves, Priscila H; Wyvill, Kathleen M et al. (2017) A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. Oncologist 22:505-e49
Madan, Ravi A; Karzai, Fatima H; Ning, Yang-Min et al. (2016) Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU Int 118:590-7
Goey, Andrew K L; Sissung, Tristan M; Peer, Cody J et al. (2016) Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol 56:461-73
Akshintala, Srivandana; Marcus, Leigh; Warren, Katherine E et al. (2015) Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer 62:603-10
Roth, Jeffrey; Peer, Cody J; Widemann, Brigitte et al. (2014) Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 970:95-101

Showing the most recent 10 out of 40 publications